Zimmer Biomet lands $2.75B in new credit lines, swaps out 2025 facilities
What's the deal? Zimmer BiometDealroom has a profile for this one. Try Dealroom → has secured $2.75 billion in unsecured borrowing capacity through two new revolving credit agreements signed on June 26, 2026.
The first is a five-year, $1.5 billion facility maturing in June 2031, with JPMorgan Chase BankDealroom has a profile for this one. Try Dealroom → as administrative agent. It allows two optional one-year extensions and up to $750 million in added capacity.
The second is a 364-day, $1.25 billion facility, also run by JPMorganDealroom has a profile for this one. Try Dealroom →, maturing in June 2027. Both carry floating rates tied to the medical device maker's credit rating.
Proceeds are earmarked for general corporate purposes.
Why now? The new lines replace Zimmer Biomet's prior five-year and 364-day agreements, both dated June 27, 2025.
Neither old facility carried an outstanding balance at termination. The company paid roughly $400,000 in fees to close out the five-year deal.
What could go wrong? The agreements cap the company's debt-to-EBITDA ratio at 4.5 to 1.0, loosening to 5.0 to 1.0 for a qualified material acquisition.
Floating rates also leave the firm exposed to swings in borrowing costs if rates climb.
The signal: As a mature medtech player specialising in personalised joint replacement technology, Zimmer Biomet's move to refresh — rather than draw down — its credit lines fits the profile of a company positioning for opportunistic dealmaking. The acquisition carve-out in the covenants reinforces that read, leaving headroom for a major buy in an industry where consolidation remains a key growth lever.
Read more: StreetInsider
Image credit: USDAgov
